<DOC>
	<DOCNO>NCT02173639</DOCNO>
	<brief_summary>The objective ass relative bioavailability pilot scale linagliptin 2.5 mg / metformin 1000 mg fix dose combination ( FDC ) tablet comparison single tablet linagliptin 2.5 mg metformin 1000 mg administer together .</brief_summary>
	<brief_title>Bioavailability Combination Tablet BI 1356/Metformin Compared With Single BI 1356 Metformin Administered Together Healthy Male Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Healthy male female base upon complete medical history , include physical examination , vital sign ( Blood Pressure , Pulse Rate ) , 12lead Electrocardiogram , clinical laboratory test Age ≥18 ≤ 55 year BMI ≥18.5 ≤29.9 kg/m2 ( Body Mass Index ) Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation Any finding medical examination deviate normal clinical relevance . Repeated measurement systolic blood pressure great 140 mm Hg diastolic blood pressure great 90 mm Hg Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug within one month le 10 halflives respective drug prior first study drug administration trial except relevant interaction rule Participation another trial investigational drug within two month prior first study drug administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke pharmacokinetic study day Alcohol abuse ( average consumption 20 g/day female 30 g/day male ) Drug abuse Blood donation ( 100 mL within four week prior start study ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) A history additional risk factor Torsade de Pointes ( TdP ) ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) For female subject : Positive pregnancy test , pregnancy plan become pregnant study within 2 month study completion No adequate contraception study 2 month study completion , i.e . follow : implant , injectables , combine oral contraceptive , IUD ( intrauterine device ) , sexual abstinence least 1 month prior enrolment , vasectomised partner ( vasectomy perform least 1 year prior enrolment ) , surgical sterilisation ( include hysterectomy ) . Females , vasectomise partner , sexually abstinent surgically sterile ask use additional barrier method ( e.g . condom , diaphragm spermicide ) Lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>